Hemostemix Inc.

HEM

CA4236943060

Biotechnology & Medical Research

Delayed Toronto S.E. Other stock markets 16:35:29 02/07/2024 BST			5-day change	1st Jan Change
0.06 ^CAD	-14.29%		+50.00%	-14.29%

06-11	Hemostemix Announces Strategic Manufacturing Partnership with Cytoimmune Therapuetics	CI
06-03	Hemostemix Inc. announced that it expects to receive CAD 2 million in funding	CI

Hemostemix Inc. Announces Resignation of Robert Bard as Director

January 05, 2017 at 09:38 pm

Hemostemix Inc. announced the resignation of Robert Bard as a director of the company effective December 15, 2016.

Latest news about Hemostemix Inc.

Hemostemix Announces Strategic Manufacturing Partnership with Cytoimmune Therapuetics	06-10	CI
Hemostemix Inc. announced that it expects to receive CAD 2 million in funding	06-02	CI
Hemostemix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-30	CI
Hemostemix Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-30	CI
Hemostemix Announces Updated Phase II Randomized Clinical Trial Results Published by the Journal of Biomedical Research and Environmental Sciences	02-06	CI
Hemostemix Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-29	CI
Hemostemix Inc. Announces That 4Th Heart Study Published in Stem Cell Research & Therapy Confirms Treatment for Heart Disease	31/10/23	CI
Hemostemix Closed Private Placement	03/10/23	MT
Hemostemix Inc. announced that it has received CAD 0.320385 million in funding	02/10/23	CI
Hemostemix Inc. announced that it expects to receive CAD 0.325125 million in funding	27/09/23	CI
Hemostemix Inc. announced that it has received CAD 0.72754 million in funding	26/09/23	CI
Hemostemix Inc. Announces Its Study of NCP-01 Supporting Brain Computer Interfaces Has Been Submitted for Peer Review Publication	15/09/23	CI
Hemostemix Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	28/08/23	CI
Hemostemix Inc. Submits its Retrospective Heart Study to Leading Stem Cell Journal	10/08/23	CI
Hemostemix Completes Private Placement; Down 4.2%	28/06/23	MT
Hemostemix Inc. announced that it has received CAD 0.40354 million in funding	27/06/23	CI
Transcript : Hemostemix Inc. - Shareholder/Analyst Call	09/06/23
Hemostemix Inc. announced that it expects to receive CAD 1.2 million in funding	31/05/23	CI
Hemostemix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	29/05/23	CI
Hemostemix Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	01/05/23	CI
Hemostemix Inc. announced that it has received CAD 0.7624 million in funding	20/03/23	CI
Hemostemix Inc. announced that it expects to receive $17.5 million in funding	06/03/23	CI
Hemostemix Inc. announced that it expects to receive CAD 3.36 million in funding	31/01/23	CI
Hemostemix Announces Award of Japanese Patent	26/01/23	MT
Hemostemix Hiring Four Biotechnologists in Montreal, Says Applying for Grants to Fund up to 75% of 5-Year Costs	23/01/23	MT

Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patientâs blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patientâs blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01, its lead clinical-stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. ACP-01 is in a Phase 2 clinical trial in Canada and the United States. Its technology includes methods for collecting the synergetic cell population and manufacturing a personalized regenerative therapy that can be administered to a patient within seven days of the initial cell collection. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd. and PreCerv Inc.

Sector

Biotechnology & Medical Research

Calendar

25/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
HEMOSTEMIX INC.	-14.29%	4.44M
VERTEX PHARMACEUTICALS INCORPORATED	+16.40%	122B
REGENERON PHARMACEUTICALS, INC.	+17.35%	114B
ARGENX SE	+19.62%	25.71B
BIONTECH SE	-25.98%	19.02B
GENMAB A/S	-20.21%	15.83B
BEIGENE, LTD.	-19.83%	15.32B
WUXI APPTEC CO., LTD.	-47.37%	14.88B
SAREPTA THERAPEUTICS, INC.	+59.98%	14.82B
NEUROCRINE BIOSCIENCES, INC.	+4.91%	14.1B

Bio Therapeutic Drugs

Hemostemix Inc.

Equities

HEM

CA4236943060

Biotechnology & Medical Research

Hemostemix Inc. Announces Resignation of Robert Bard as Director

Latest news about Hemostemix Inc.

Chart Hemostemix Inc.

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs